Weight loss interventions were statistically significantly associated with improvements in biomarkers, including alanine aminotransferase (–9.81 U/L; 95% CI, –13.12 to –6.50; I2 = 97%), histologically or radiologically measured liver steatosis (standardized mean difference: –1.48; 95% CI, –2.27 to –0.70; I2 = 94%), histologic NAFLD activity score (–0.92; 95% CI, –1.75 to –0.09; I2 = 95%), and presence of nonalcoholic steatohepatitis (OR, 0.14; 95% CI, 0.04-0.49; I2 = 0%). The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.